Duke Asthma, Allergy & Airway Center
Jump to Main Content

Clinical Trials

 

Active Studies

Asthma:

Vitamin D add-on therapy enhances corticosteroid responsiveness in Asthma (VIDA) VIDA is a study aimed at improving the health of people with asthma who still have asthma symptoms despite using low dose inhaled asthma medications (inhaled corticosteroids) and who are deficient in vitamin D.
 
Eligibility Requirements
    •    Age 18+
Persistent asthma symptoms use of low dose inhaled corticosteroid Low vitamin D levels(<30 ng/ml) Vitamin D supplements < 1000 IU/day
 
Research Study Requirements
1)   Undergo a screening visit
2)   Take study medications that are provided at no cost to you
3)   A total of 11 visits over 35 weeks
 
Compensation Financial compensation will be provided for qualified participants.   

 
For more information, contact Denise Beaver at 919-479-0743 or denise.beaver@duke.edu.  (Ref# 27628)  
 
A Randomized, Double-Blind, Placebo-Controlled, Cross-over Study to evaluate the effect of Singulair® plus moderate dose beclomethasone (QVar®) compared to high dose beclomethasone (QVar®) in obese subjects with moderate persistent asthma (MERCK Obesity Study).
The purpose of this study to to compare the effectiveness of two asthma management approaches used to treat asthma (moderate does inhaled corticosteroids plus Singulair®, and high dose inhaled corticosteroids alone. This is a cross-over study, which means you will receive both treatments at different points in the study.
 
Airway Remodeling in Asthma: Modulation by Interleukin-13 (IRB 8848, NIH sponsored). This is a study to evaluate whether or not the cytokine interleukin-13 modulates airway fibroblast function in asthma via increased expression of PDGF. Asthmatic patients with a post bronchodilator FEV1>50% and stable symptoms are eligible for study. Subjects are adult asthmatics who are not using inhaled steroids or leukotriene modifiers. Study involves methacholine challenge, chest x-ray, complete pulmonary function testing and routine labs for screening.
 
GSNO reductase, S-nitrosothiols, and Asthma (GSNO): This study will assess the loss of S-nitrosothiols which are naturally occurring airway dilators in the lungs in asthma. Study involves methacholine challenge, chest x-ray and routine labs for screening.
 
If you are interested in participating in any of these above studies or have any questions please contact our lead study coordinator Denise Beaver by phone at 919 479-0719 or Email  denise.beaver@duke.edu .
__________________________________________________________________________________________________________
 
Study of Acid Reflux in Children with Asthma (SARCA Study)
        What is the purpose of this study? 
         Physicians at the Duke Asthma Clinical Research Center (ACRC) are studying acid reflux (GER) and asthma. Asthma may be hard to control because of GER. Children with asthma may be    eligible for the study even without symptoms of acid reflux. 
           What does this study involve? 
          The study involves nine visits over a six month time period. Individuals 6 to 17 years old may be eligible to participate in this study.
         Subjects receive: Testing for gastroesophageal reflux (GER), study medication, lung function testing and compensation for participation
 
For further information, please call Catherine Foss, RRT, CCRC or Denise Jaggers, RN at 919-684-0191.

If you are interested in participating in this study, email DukeACRC@mc.duke.edu and provide your contact information (email and/or phone number). A research coordinator will follow up with you by phone.   (Ref # e-0739)

 
 
Methacholine Broncoprovocation Influence of High Potency Corticosteroids in Asthma (MeCIS)
        What is the purpose of this study?
        The American Lung Association and physicians at the Duke Asthma Clinical Research Center are interested in learning more about the influence
        of high potency corticosteroids in asthma.
        What does this study involve for asthma participants?
        The study involves five visits over a three month time period for asthma participants. Participants with asthma must be diagnosed by a physician   
        and under good control (few or no asthma symptoms during the last four weeks).
        Subjects may receive: Allergy skin testing, lung function testing, study medication, compensation for participation
 
        What does this study involve for healthy participants?
        The study involves one visit for healthy/non-asthmatic participants. Eligible participants must have no history of asthma or allergies and be    
        a nonsmoker.
        Subjects may receive: Allergy skin testing, lung function testing, compensation for participation

For further information, please call John Sundy, MD, Cathy Foss, RRT, CCRC, or Denise Jaggers, RN at 919-684-0191.
If you are interested in participating in this study, email
 

DukeACRC@mc.duke.edu and provide your contact information (email and/or phone number). A research coordinator will follow up with you by phone.(Ref #e-9088)

_________________________________________________________________________________________________________________

COPD:

Metabolomic and Inflammatory Profiling in Patients with COPD: The purpose of this study is to examine systemic changes in metabolism, hormones, and inflammation following standard treatment with combination of salmeterol 50mcg and fluticasone propionate 250 mcg. Study involves chest x-ray, complete pulmonary function testing, and routine labs for screening.

If you are interested in referring patients for any of these studies or have any questions please contact our lead study coordinator Denise Beaver by phone at 919 479-0719 or Email  denise.beaver@duke.edu .

COPD:

The Long-term Oxygen Therapy Trial (LOTT): This is trial of oxygen therapy sponsored by the National Heart, Lung, and Blood Institute of the NIH. The trial will investigate whether there is a long-term benefit to round-the-clock oxygen therapy in patients with moderately severe COPD and moderately low blood oxygen levels. Further information can be found from the NIH press release
 

Printer Friendly PageSend this Story to a Friend
© 2013, Duke University Health System   DHTS Web Services DHTS Web Services